Factor Therapeutics Receives $3.1M R&D Tax Incentive

Brisbane, Australia 5th December 2017: Factor Therapeutics Limited (ASX: FTT, the "Company"), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to confirm that it has received $3.1M in Research & Development (R&D) tax incentive for the year ending 30 June 2017.

The incentive is an Australian Government initiative to encourage companies to engage in R&D that benefits Australia. Factor's receipt of this incentive reflects the company's strong focus on clinical development – through its Phase 2b study VF00102 in venous leg ulcers – and a modest investment in progressing other assets in the company's portfolio, including its ocular programme and collaboration with Monash University.

-ENDS-

For Further Information Contact

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit https://factor-therapeutics.com.